

THE GUIDELINE ADVANTAGE FACT SHEET

OVERVIEW

The Guideline Advantage™ combines the expertise of the American Cancer Society, American Diabetes Association and American Heart Association (ACS, ADA, AHA) to advance prevention and disease management in the outpatient setting. The program promotes the use of evidence-based treatment guidelines, performance measurement tools and quality improvement strategies with the goal of helping you offer your patients every advantage for a healthy life.

The Guideline Advantage supports quality preventive care and disease management by:

- Working with data already in practices' Electronic Health Records (EHRs), requiring no additional data entry
- Providing on-demand access to quality improvement data via a web-based platform
- Offering system, practice and physician-level measure reporting
- Benchmarking performance internally and externally at state and national levels
- Recognizing practices for participation and quality improvement achievement
- Delivering quality improvement resources, knowledge sharing and research
- Aligning with the Million Hearts initiative performance measures and UDS (Uniform Data Systems) adult quality measures
- Including functionality to initiate quality improvement directly from the platform using patient action lists

PROGRAM DESCRIPTION

The Guideline Advantage transforms outpatient practice data into actionable data to improve the quality of patient care.

Participating practices can choose one of two program models:

- The Basic Model provides reporting on two measure sets as well as patient panels, demographic information and benchmarking. There is no cost for the Basic Model.
- The Premium Model provides enhanced functionality and customer-driven functionality options. The program's technology vendor will provide comprehensive data consultation and guidance. Installation and licensing fees will be assessed for Premium Model users.

Currently, the program captures many of the Meaningful Use Stage 1 core clinical quality measures most directly related to conditions and risk factors of interest to the ACS/ADA/AHA. Additionally, The Guideline Advantage reports on the measures of interest to the Million Hearts™ initiative created by the Department of Health and Human Services and the Uniform Data System's (UDS) adult quality measures.

MEASURES OVERVIEW

Measures provide the basis for evaluating and improving outpatient treatment. Initial selection of measures used in The Guideline Advantage program was based on review of nationally accepted ambulatory care measures. The program's measures will be reviewed and updated periodically to reflect measure maintenance, EHR reporting changes and alignment with national programs. Corresponding changes may be made in data elements requested for collection.

The Guideline Advantage program includes two primary measure sets:

- Reporting Measure Set will be calculated with strict adherence to the definitions provided by the measure developer.
- The Guideline Advantage Common Measure Set is intended to provide quality improvement feedback based on a simplified version of established measures. These simplified versions of the established measures may have similar titles or measure descriptions to existing measures, but may have different measure constructs.

FUNCIONALITY BASIC VS. PREMIUM

FUNCIONALITY	BASIC	☆ PREMIUM
DATA SUBMISSION GUIDANCE	×	×
MANUAL DATA UPLOAD	×	
FORWARD HEALTH GROUP DATA SERVICE		×
THE GUIDELINE ADVANTAGE QI MEASURE SET	×	×
THE GUIDELINE ADVANTAGE REPORTING MEASURE SET	×	×
CUSTOM MEASURE SET(S)		×
CUSTOM POPULATION TRACKING		×
CUSTOM MEASURE TRACKING		×
MANUAL PATIENT ATTRIBUTION	×	
CUSTOM PATIENT ATTRIBUTION		×
VISUALIZATION TOOLKIT	×	×
ENHANCED VISUALIZATION TOOLKIT		×
THE GUIDELINE ADVANTAGE BENCHMARKING	×	×
CUSTOM BENCHMARKING		×
ACTION LISTS	×	×
ACCOUNTABLE CARE ORGANIZATION SUPPORT		×
PAY FOR PERFORMANCE MONITORING		×
CUSTOM REPORTS		×
COST TO PARTICIPATE		×

THE GUIDELINE ADVANTAGE COMMON MEASURE SET DEFINITIONS

CORONARY ARTERY DISEASE

LDL-C Test: Percentage of patients aged 18 years and older with an LDL test during the 12 month measurement period.

LDL-C Control: Percentage of patients aged 18 years and older with a diagnosis of CAD with most recent LDL-C <100 mg/dL.

Drug Therapy for Lowering LDL-C: Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed a lipid-lowering therapy.

Antiplatelet Therapy: Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed aspirin or clopidigrel.

Blood Pressure Screening: Percentage of patients aged 18 years and older with a diagnosis of CAD whose blood pressure was screened

High Blood Pressure Control: Percentage of patients aged 18 years and older with a diagnosis of CAD whose blood pressure was adequately controlled (<140/90 mmHg)

High Blood Pressure Drug Therapy: Percentage of patients aged 18 years and older with a diagnosis of CAD whose blood pressure was greater than or equal to 140/90 mmHg and were prescribed 2 or more antihypertensives

Tobacco Use Screening: Percentage of patients aged 18 years and older with a diagnosis of CAD screened for tobacco use within 24 months

Tobacco Use Cessation Intervention: Percentage of patients aged 18 years and older with a diagnosis of CAD who are tobacco users that received cessation intervention within 24 months

BMI Testing: Percentage of patients aged 18 years and older with a diagnosis of CAD with a BMI calculated within 6 months

BMI Follow-up: Percentage of patients aged 18 years and older with a diagnosis of CAD with a BMI calculated within 6 months that is outside of the expected parameters and have a documented follow-up plan

BMI Outside Expected Parameters: Percentage of patients aged 18 years and older with a diagnosis of CAD with a BMI within 6 months that is outside of the expected parameters

CANCER SCREENING

Cervical Cancer Screening: Percentage of female patients aged 21 through 63 years who received one or more Pap tests within 3 years

Colorectal Cancer Screening: Percentage of patients aged 50 through 75 years who received the appropriate colorectal cancer screening

Mammography Screening: Percentage of female patients aged 40 through 69 years who had a mammogram to screen for breast cancer within 24 months

DIABETES MELLITUS

Hemoglobin A1c Test: Percentage of patients aged 18 through 75 years with a current diagnosis of diabetes mellitus with hemoglobin A1c tested within 12 months

Hemoglobin A1c Control: Percentage of patients aged 18 through 75 years with a current diagnosis of diabetes mellitus with their most recent hemoglobin A1c less than 7.0%, between 7.0% and 7.9%, between 8.0% and 9.0%, or greater than 9.0%

LDL-C Test: Percentage of patients aged 18 through 75 years with a current diagnosis of diabetes mellitus with an LDL test within 12 months

LDL-C Control: Percentage of patients aged 18 through 75 years with a current diagnosis of diabetes mellitus with most recent LDL less than 100 mg/dL

Blood Pressure Screening: Percentage of patients aged 18 through 75 years with a current diagnosis of diabetes mellitus whose blood pressure was screened within 12 months

High Blood Pressure Control: Percentage of patients aged 18 through 75 years with a current diagnosis of diabetes mellitus whose blood pressure was adequately controlled (<140/80 mmHg)

Urine Albumin Testing: Percentage of patients aged 18 through 75 years with a current diagnosis of diabetes mellitus with urine albumin tested within 12 months

HYPERTENSION

Blood Pressure Screening: Percentage of patients aged 18 through 85 years with a diagnosis of hypertension whose blood pressure was screened within 12 months

High Blood Pressure Control: Percentage of patients aged 18 through 85 years with a diagnosis of hypertension whose blood pressure was adequately controlled (<140/90 mmHg)

THE GUIDELINE ADVANTAGE COMMON MEASURE SET DEFINITIONS

ISCHEMIC VASCULAR DISEASE

Use of Aspirin or Other Antithrombotic: Percentage of patients aged 18 years and older with a current diagnosis of IVD with documented use of aspirin or other antithrombotic

LDL-C Test: Percentage of patients aged 18 years and older with a current diagnosis of IVD with an LDL test within 12 months

LDL-C Controlled: Percentage of patients aged 18 years and older with a current diagnosis of IVD with most recent LDL-C less than 100 mg/dL

PREVENTIVE CARE AND SCREENING

Blood Pressure Screening: Percentage of patients aged 18 years and older whose blood pressure was measured within 24 months

Tobacco Users: Percentage of patients aged 18 years and older who are tobacco users

Tobacco Use Screening: Percentage of patients aged 18 years and older screened for tobacco use within 24 months

Tobacco Use Cessation Intervention: Percentage of patients aged 18 years and older who are tobacco users that received cessation intervention within 24 months

Tobacco Use Pneumococcal Immunization: Percentage of patients aged 18 years and older who are tobacco users who have ever received a pneumococcal immunization

BMI Testing: Percentage of patients aged 18 years and older with a BMI calculated within 6 months

BMI Outside Expected Parameters: Percentage of patients aged 18 years and older with a BMI within 6 months that is outside of the expected parameters

BMI Follow-Up: Percentage of patients aged 18 years and older with a BMI within 6 months that is outside of the expected parameters and have a documented follow-up plan

Influenza Immunization: Percentage of patients aged 18 years and older who received or reported receipt of an influenza immunization

LDL-C Test: Percentage of patients aged 18 years and older with an LDL test within 5 years

THE GUIDELINE ADVANTAGE REPORTING MEASURE SET

The Guideline Advantage Reporting Measure Set consists of measures included in Universal Data System (UDS) from the Health Resources and Services Administration's (HRSA) Health Center Program and the Million Hearts™ initiative created by the Department of Health and Human Services. Both of these programs utilize measures from the Physician Quality Reporting System (PQRS) and will be calculated with strict adherence to those definitions.

HYPERTENSION

Hypertension: Controlling High Blood Pressure: Percentage of patients aged 18 through 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90 mmHG). (NQF 0018/PQRS #236, Million Hearts & UDS)

ISCHEMIC VASCULAR DISEASE

Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic: Percentage of patients aged 18 years and older with ischemic vascular disease with documented use of aspirin or other antithrombotic. (NQF 0068/PQRS #204, Million Hearts & UDS)

Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control: Percentage of patients aged 18 years and older with ischemic vascular disease who received at least one lipid profile within 12 months and whose most recent LDL-C level in control (less than 100 mg/dL) (NQF 0075/PQRS #241, Million Hearts)

CORONARY ARTERY DISEASE

Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol: Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines) (NQF 0074/PQRS #197, UDS)

CANCER

Screening mammography: Percentage of women aged 40 through 69 years who had a mammogram to screen for breast cancer within 24 months. (NQF 0031/PQRS #112)

Colorectal cancer screening: Percentage of patients aged 50 through 75 years who received the appropriate colorectal cancer screening. (NQF 0034/PQRS #113, UDS)

Cervical Cancer Screening: Percentage of women aged 21 through 63 years who received one or more Pap tests to screen for cervical cancer (NQF 0032/PQRS #309, UDS)

DIABETES MELLITUS

Hemoglobin A1c Poor Control in Diabetes Mellitus: Percentage of patients aged 18 through 75 years with diabetes mellitus who had most recent hemoglobin A1c greater than 9.0%. (NQF 0059/PQRS #1, UDS)

Diabetes Mellitus: Hemoglobin A1c Control (<8%): The percentage of patients 18 through 75 years of age with a diagnosis of diabetes (type 1 or type 2) who had HbA1c < 8%. (NQF 0575/PQRS #313, UDS)

Low-Density Lipoprotein (LDL-C) Control in Diabetes Mellitus: Percentage of patients aged 18 through 75 years with diabetes mellitus who had most recent LDL-C level in control (less than 100 mg/dL) (NQF 0064/PQRS #2, Million Hearts)

ASTHMA

Asthma: Pharmacological Therapy: Percentage of patients aged 5 through 50 years with a diagnosis of mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment. **The Guideline Advantage only reports on patients 18 years and older* (NQF 0047/PQRS #53, UDS)

PREVENTIVE CARE AND SCREENING FOR CHRONIC DISEASES AND STROKE

Body Mass Index (BMI) Screening and Follow-Up: Percentage of patients aged 18 years and older with a calculated BMI in the past six months or during the current visit documented in the medical record AND if the most recent BMI is outside of normal parameters, a follow-up plan is documented. (NQF 0421/PQRS #128, UDS)

Tobacco Use: Screening and Cessation Intervention: Percentage of patients aged 18 years or older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user. (NQF 0028/PQRS #226, Million Hearts, UDS)

Cholesterol – Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL: Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDL test performed and whose risk-stratified fasting LDL is at or below the recommended LDL goal. (PQRS #316, Million Hearts)

Screening for High Blood Pressure: Percentage of patients aged 18 and older who are screened for high blood pressure. (PQRS #317, Million Hearts)